CSL Behring Launches GameFaces™ Program at National Hemophilia Foundation Annual Meeting
Interactive online initiative provides six months of physical challenges for patients with hemophilia A
Denver, CO — 19 November 2008
CSL Behring announced today it launched the first challenge of GameFaces™, a family-oriented online initiative for patients with hemophilia A, at the 60th Annual Meeting of the National Hemophilia Foundation (NHF). GameFaces is designed to encourage real-life physical activity through a series of three customized challenges based on the individual's age, disease severity and current level of physical activity. Participants can now log on to the program website at www.HFSGameFaces.com, create their GameFaces character and begin the first challenge, which will run from today through January 10, 2009.
CSL Behring, the providers of the hemophilia treatment Helixate® FS (Antihemophilic Factor, Recombinant), developed GameFaces to inspire hemophilia A patients to participate in physical activities and also to allow them to feel connected to other patients with this serious bleeding disorder. At the conclusion of each challenge period, those who have completed the challenge will be entered into a drawing to win a Nintendo® Wii™ game console. Nintendo Wii has been recognized as the next generation of video games and is known to inspire physical activity through games that require movement.
"We are pleased to officially unveil GameFaces to the hemophilia community at the NHF's annual meeting, where the theme this year is ‘Reaching New Heights'," said Garrett E. Bergman, M.D., Senior Director, Medical Affairs, U.S. Commercial Operations at CSL Behring. "GamesFaces promotes the kind of daily physical activity that will empower hemophilia A patients, from those with a mild form of the condition to those with the most severe form, to reach new heights in developing a healthy and safe lifestyle."
"We appreciate CSL Behring's commitment to our children and their specific needs,” said Rhonda Boni-Burden, mother of Alex, a 14-year-old boy with severe hemophilia A. "A program like GameFaces enables our children to build their self-esteem and helps manage these bleeding disorders, which is important to our families' quality of life.”
The program's physical challenges include both outdoor and indoor activities, which patients can complete on their own or with family and friends. The second and third challenges will occur in 2009 from January 10 through March 7 and from March 7 through May 2, respectively. Challenges are designed to be completed over a one-month timeframe during the challenge interval. Participants can track their progress by logging on to the program's website at www.HFSGameFaces.com. Children under 18 must have a parent's permission to participate.
Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 15,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.
About Helixate FS
Helixate FS is a recombinant factor VIII product indicated for the treatment of hemophilia A that offers convenient administration with a 2.5-mL volume diluent; no available factor VIII product has a smaller diluent size. The 2000 vial size requires a 5.0 mL volume diluent.
No albumin is used in the formulation or purification of Helixate FS, and its manufacture includes a solvent/detergent viral inactivation step. The most frequently reported adverse event is local injection-site reaction. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Helixate FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate FS. In 2006, the FDA gave approval for Helixate FS to be stored at room temperature (up to 25°C, 77°F) for three months. The storage guidelines for the hemophilia treatment provide users with greater flexibility and simplify storage options
Helixate® FS is manufactured by Bayer HealthCare LLC for CSL Behring LLC.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.
Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations